{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:41Z","timestamp":1786991621426,"version":"build-2736575974"},"reference-count":152,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jceh.2017.12.001","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T18:34:09Z","timestamp":1513449249000},"page":"58-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements"],"prefix":"10.1016","volume":"8","author":[{"given":"Anil","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaram P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-7227","authenticated-orcid":false,"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek A.","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad","family":"Devarbhavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod K.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhabadev","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmesh","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Nijhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh R.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrivikrama","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varghese","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Wadhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10003","key":"10.1016\/j.jceh.2017.12.001_bib0765","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib0770","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jceh.2014.12.004","article-title":"Tackling the hepatitis B disease burden in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2017.12.001_bib0775","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0780","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2017.12.001_bib0790","series-title":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection","year":"2015"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0795","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3350\/cmh.2016.22.1.18","article-title":"KASL clinical practice guidelines: management of chronic hepatitis B","volume":"22","author":"Korean Association for the Study of the Liver","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"7454","key":"10.1016\/j.jceh.2017.12.001_bib0800","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib0805","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1440-1746.1993.tb01551.x","article-title":"Natural history of chronic hepatitis B virus infection: new light on an old story","volume":"8","author":"Chen","year":"1993","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jceh.2017.12.001_bib0810","first-page":"663","article-title":"Systematic review and meta-analysis of prevalence of hepatitis B in India","volume":"44","author":"Batham","year":"2007","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib0815","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jmv.1890210205","article-title":"Dynamics and impact of perinatal transmission of hepatitis B virus in North India","volume":"21","author":"Nayak","year":"1987","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib0820","first-page":"190","article-title":"Hepatitis B\u2014potential of perinatal transmission in India","volume":"17","author":"Mittal","year":"1996","journal-title":"Trop Gastroenterol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib0825","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12664-011-0083-y","article-title":"Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission","volume":"30","author":"Dwivedi","year":"2011","journal-title":"Indian J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib0830","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/jmv.22017","article-title":"Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India","volume":"83","author":"Pande","year":"2011","journal-title":"J Med Virol"},{"issue":"11","key":"10.1016\/j.jceh.2017.12.001_bib0835","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jvh.12102","article-title":"Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial","volume":"20","author":"Pande","year":"2013","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0840","first-page":"19","article-title":"Hepatitis B virus genotype A is more often associated with severe liver disease in northern India than is genotype D","volume":"24","author":"Kumar","year":"2005","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.12.001_bib0845","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1743-422X-5-156","article-title":"An overview of molecular epidemiology of hepatitis B virus (HBV) in India","volume":"5","author":"Datta","year":"2008","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib0850","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/jmv.10292","article-title":"Hepatitis B virus genotypes and serotypes in western India: lack of clinical significance","volume":"69","author":"Gandhe","year":"2003","journal-title":"J Med Virol"},{"issue":"37","key":"10.1016\/j.jceh.2017.12.001_bib0855","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.3748\/wjg.v12.i37.5964","article-title":"Distribution of hepatitis B virus genotypes: phylogenetic analysis and virological characteristics of genotype C circulating among HBV carriers in Kolkata, Eastern India","volume":"12","author":"Banerjee","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.jceh.2017.12.001_bib0860","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/jmv.20677","article-title":"Phylogenetic relatedness and genetic diversity of hepatitis B virus isolates in Eastern India","volume":"78","author":"Banerjee","year":"2006","journal-title":"J Med Virol"},{"issue":"41","key":"10.1016\/j.jceh.2017.12.001_bib0865","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.3748\/wjg.v12.i41.6702","article-title":"Hepatitis B virus genotypes in chronic liver disease patients from New Delhi, India","volume":"12","author":"Chattopadhyay","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib0870","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1440-1746.2002.02605.x","article-title":"Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent","volume":"17","author":"Thakur","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jceh.2017.12.001_bib0875","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1086\/383144","article-title":"Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India","volume":"38","author":"Vivekanandan","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"40","key":"10.1016\/j.jceh.2017.12.001_bib0880","first-page":"405","article-title":"Hepatitis B vaccines","volume":"84","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib0885","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J Infect Dis"},{"issue":"23\u201324","key":"10.1016\/j.jceh.2017.12.001_bib0890","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/S0264-410X(99)00178-4","article-title":"Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age","volume":"17","author":"Viviani","year":"1999","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jceh.2017.12.001_bib0895","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/INF.0b013e31817702ba","article-title":"Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study","volume":"27","author":"Bialek","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"5\u20136","key":"10.1016\/j.jceh.2017.12.001_bib0900","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.vaccine.2003.09.001","article-title":"Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers","volume":"22","author":"Floreani","year":"2004","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.jceh.2017.12.001_bib0905","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2017.12.001_bib0910","unstructured":"Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of Vaccines and Immune Globulins in Persons with Altered Immunocompetence. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00023141.htm Accessed 20.05.17."},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib0915","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0255-0857.96664","article-title":"Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: a cross-sectional study","volume":"30","author":"Gupta","year":"2012","journal-title":"Indian J Med Microbiol"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib0925","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4103\/0377-4929.85074","article-title":"Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters","volume":"54","author":"Rastogi","year":"2011","journal-title":"Indian J Pathol Microbiol"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib0930","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1478-3231.2008.01711.x","article-title":"Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus","volume":"28","author":"Kumar","year":"2008","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib0935","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/apt.13488","article-title":"Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B","volume":"43","author":"Li","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib0940","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3748\/wjg.v23.i4.687","article-title":"Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: a study of 326 patients from India","volume":"23","author":"Kumar","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib0945","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12664-014-0491-x","article-title":"Usefulness of transient elastography by FibroScan for the evaluation of liver fibrosis","volume":"33","author":"Sharma","year":"2014","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib0950","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jceh.2015.09.004","article-title":"Role of transient elastography (FibroScan) in differentiating severe acute hepatitis and acute on chronic liver failure","volume":"5","author":"Sharma","year":"2015","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-016-9760-3","article-title":"Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update","volume":"11","author":"Shiha","year":"2017","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0960","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado","year":"2015","journal-title":"J Hepatol"},{"issue":"1 suppl","key":"10.1016\/j.jceh.2017.12.001_bib0965","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA\u2014the holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib0970","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib0975","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib0980","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jceh.2017.12.001_bib0985","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib0990","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib0995","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature","volume":"37","author":"Mommeja-Marin","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1000","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2893.2005.00603.x","article-title":"The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B","volume":"12","author":"Yuan","year":"2005","journal-title":"J Viral Hepat"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2017.12.001_bib1005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jceh.2014.04.003","article-title":"The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: the Puri recommendations","volume":"4","author":"Kumar","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jceh.2013.08.007","article-title":"Hepatitis B virus infection can cause hepatocellular carcinoma in less advanced liver cirrhosis: a comparative study of 142 patients from North India","volume":"3","author":"Arora","year":"2013","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.20110","article-title":"Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations","volume":"39","author":"Lok","year":"2004","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1020","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1025","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/hep.1840360617","article-title":"Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection","volume":"36","author":"Chu","year":"2002","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2017.12.001_bib1035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/liv.12996","article-title":"HBV: do I treat my immunotolerant patients?","volume":"36","author":"Vlachogiannakos","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cgh.2008.10.023","article-title":"Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients","volume":"7","author":"Wong","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1050","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cld.2013.05.001","article-title":"Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B","volume":"17","author":"Asselah","year":"2013","journal-title":"Clin Liver Dis"},{"issue":"9","key":"10.1016\/j.jceh.2017.12.001_bib1055","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-017-0754-9","article-title":"Tenofovir alafenamide: a review in chronic hepatitis B","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1060","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MCG.0000000000000478","article-title":"Chronic hepatitis B virus infection: disease revisit and management recommendations","volume":"50","author":"Yuen","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0033-1345718","article-title":"Antiviral therapy for chronic hepatitis B in pregnancy","volume":"33","author":"Pan","year":"2013","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1070","first-page":"59","article-title":"Renal and bone toxicity with the use of tenofovir: understanding at the end","volume":"18","author":"Casado","year":"2016","journal-title":"AIDS Rev"},{"issue":"7","key":"10.1016\/j.jceh.2017.12.001_bib1075","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14712598.2014.907784","article-title":"Peginterferon \u03b1 in the treatment of chronic hepatitis B","volume":"14","author":"Tseng","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1080","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1085","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jceh.2017.12.001_bib1090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jvh.12341","article-title":"Combination therapy of interferon and nucleotide\/nucleoside analogues for chronic hepatitis B","volume":"21","author":"Wong","year":"2014","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1095","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1665-2681(19)31000-2","article-title":"Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review","volume":"12","author":"Lieveld","year":"2013","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2010.06.016","article-title":"Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B","volume":"54","author":"Chotiyaputta","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2893.2011.01494.x","article-title":"Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs","volume":"19","author":"Chotiyaputta","year":"2012","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1110","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2010.06.053","article-title":"Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection","volume":"139","author":"Berg","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3851\/IMP1944","article-title":"The role of adherence in virological suppression in patients receiving anti-HBV analogues","volume":"17","author":"Sogni","year":"2012","journal-title":"Antivir Ther (Lond)"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4254\/wjh.v4.i2.43","article-title":"Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires","volume":"4","author":"Giang","year":"2012","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1125","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jhep.2011.04.006","article-title":"Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?","volume":"55","author":"Hilleret","year":"2011","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jceh.2017.12.001_bib1135","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1145","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"42","key":"10.1016\/j.jceh.2017.12.001_bib1150","doi-asserted-by":"crossref","first-page":"15931","DOI":"10.3748\/wjg.v20.i42.15931","article-title":"Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B","volume":"20","author":"Kim","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1155","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na\u00efve patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.jceh.2017.12.001_bib1165","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2165\/10482940-000000000-00000","article-title":"Tenofovir disoproxil fumarate: in chronic hepatitis B","volume":"69","author":"Perry","year":"2009","journal-title":"Drugs"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2017.12.001_bib1170","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0168-8278(12)60012-9","article-title":"Management of treatment failure in chronic hepatitis B","volume":"56","author":"Zoulim","year":"2012","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2017.12.001_bib1175","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/liv.12069","article-title":"Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance","volume":"33","author":"Zoulim","year":"2013","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1180","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jhep.2013.07.017","article-title":"Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype","volume":"59","author":"Brunetto","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1185","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.antiviral.2012.12.023","article-title":"Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants","volume":"97","author":"Sonneveld","year":"2013","journal-title":"Antiviral Res"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1195","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1200","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.23323","article-title":"Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1210","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1215","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: liver transplantation","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1225","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2011.08.026","article-title":"The option of HBIG-free prophylaxis against recurrent HBV","volume":"56","author":"Fox","year":"2012","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jceh.2017.12.001_bib1230","doi-asserted-by":"crossref","first-page":"e104480","DOI":"10.1371\/journal.pone.0104480","article-title":"Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1235","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/tid.12434","article-title":"Tenofovir\/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients","volume":"17","author":"Fern\u00e1ndez","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1240","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management","volume":"15","author":"Huprikar","year":"2015","journal-title":"Am J Transpl"},{"issue":"9349","key":"10.1016\/j.jceh.2017.12.001_bib1245","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1250","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study","volume":"47","author":"Br\u00e4u","year":"2007","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1255","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hiv.12322","article-title":"Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons","volume":"17","author":"Ryom","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.jceh.2017.12.001_bib1260","unstructured":"HIV\/AIDS Guidelines\u2014AdultandAdolescentGL.pdf. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf Accessed 09.06.17."},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1265","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0000000000001069","article-title":"Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-1\/hepatitis B-coinfected adults","volume":"73","author":"Gallant","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1270","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12664-015-0555-6","article-title":"Prevalence of hepatitis D virus infection among hepatitis B virus-infected individuals in India","volume":"34","author":"Jat","year":"2015","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1275","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1440-1746.1997.tb00424.x","article-title":"Review: hepatitis delta","volume":"12","author":"Hadziyannis","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1280","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1285","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.jceh.2017.12.001_bib1290","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","article-title":"Treatment of chronic hepatitis delta with pegylated interferon-alpha2b","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1295","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1300","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jceh.2014.05.006","article-title":"Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"40","key":"10.1016\/j.jceh.2017.12.001_bib1310","doi-asserted-by":"crossref","first-page":"14559","DOI":"10.3748\/wjg.v20.i40.14559","article-title":"Hepatitis B virus and hepatitis C virus dual infection","volume":"20","author":"Caccamo","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1315","first-page":"221","article-title":"The spectrum of HBV\/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management","volume":"28","author":"Konstantinou","year":"2015","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1320","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s15010-004-3080-6","article-title":"Influence of chronic coinfection with hepatitis B and C virus on liver histology","volume":"32","author":"Sagnelli","year":"2004","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1325","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"Electronic address: easloffice@easloffice.eu. EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1330","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jceh.2016.07.001","article-title":"Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: update 2016","volume":"6","author":"Puri","year":"2016","journal-title":"J Clin Exp Hepatol"},{"issue":"12","key":"10.1016\/j.jceh.2017.12.001_bib1335","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3109\/00365520903329585","article-title":"HEP-NET B\/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin","volume":"44","author":"Potthoff","year":"2009","journal-title":"Scand J Gastroentero"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1340","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/jhep.2003.50171","article-title":"Long-term histologic and virologic outcomes of acute self-limited hepatitis B","volume":"37","author":"Yuki","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1345","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B","volume":"45","author":"Kumar","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1350","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"Electronic address: easloffice@easloffice.eu. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jceh.2017.12.001_bib1355","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jvh.12210","article-title":"Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial","volume":"21","author":"Wiegand","year":"2014","journal-title":"J Viral Hepat"},{"issue":"12","key":"10.1016\/j.jceh.2017.12.001_bib1360","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1055\/s-0042-120418","article-title":"Treatment of fulminant acute hepatitis B with nucles(t)id analogues is safe and does not lead to secondary chronification of hepatitis B","volume":"54","author":"Jochum","year":"2016","journal-title":"Z Gastroenterol"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1365","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10620-006-3175-2","article-title":"Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B","volume":"51","author":"Kumar","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1370","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.24109","article-title":"Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure","volume":"53","author":"Garg","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1375","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jceh.2017.12.001_bib1380","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MPG.0b013e318197196e","article-title":"Management of chronic hepatitis B in children","volume":"48","author":"Shah","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.28278","article-title":"Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1390","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.28015","article-title":"Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1395","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"issue":"6\u20137","key":"10.1016\/j.jceh.2017.12.001_bib1400","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/00365540802154769","article-title":"Treatment of chronic hepatitis B infection: an update of Swedish recommendations","volume":"40","author":"Lindh","year":"2008","journal-title":"Scand J Infect Dis"},{"issue":"RR-10","key":"10.1016\/j.jceh.2017.12.001_bib1405","first-page":"1","article-title":"CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management","volume":"62","author":"Schillie","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"RR-3","key":"10.1016\/j.jceh.2017.12.001_bib1410","first-page":"1","article-title":"Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"3\u20134","key":"10.1016\/j.jceh.2017.12.001_bib1415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000360949","article-title":"Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy","volume":"57","author":"Gerlich","year":"2014","journal-title":"Intervirology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1420","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hep.27837","article-title":"Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus","volume":"62","author":"Chen","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1425","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2014.04.038","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus","volume":"61","author":"Greenup","year":"2014","journal-title":"J Hepatol"},{"issue":"24","key":"10.1016\/j.jceh.2017.12.001_bib1430","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1435","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12664-012-0174-4","article-title":"Hepatitis B virus infection and pregnancy: a practical approach","volume":"31","author":"Kumar","year":"2012","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1440","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.28589","article-title":"Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection","volume":"64","author":"Wen","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1445","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1365-2893.2011.01492.x","article-title":"Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers","volume":"19","author":"Zou","year":"2012","journal-title":"J Viral Hepat"},{"issue":"36","key":"10.1016\/j.jceh.2017.12.001_bib1450","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1016\/j.vaccine.2012.06.036","article-title":"A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women","volume":"30","author":"Sun","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1455","first-page":"CD004790","article-title":"Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers","author":"Lee","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jceh.2017.12.001_bib1460","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1465","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1470","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jceh.2017.12.001_bib1480","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis","volume":"57","author":"Dong","year":"2013","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1485","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s12032-011-9974-0","article-title":"The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy","volume":"29","author":"Chen","year":"2012","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.jceh.2017.12.001_bib1490","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3748\/wjg.v21.i6.1738","article-title":"Management of patients with hepatitis B in special populations","volume":"21","author":"Cholongitas","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jceh.2017.12.001_bib1495","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14712598.2016.1177017","article-title":"Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders","volume":"16","author":"Vigan\u00f2","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jceh.2017.12.001_bib1500","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2015.11.009","article-title":"Lymphoproliferative disease and hepatitis b reactivation: challenges in the era of rapidly evolving targeted therapy","volume":"16","author":"Phipps","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.jceh.2017.12.001_bib1505","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/annonc\/mdw414","article-title":"Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment","volume":"27","author":"Voican","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jceh.2017.12.001_bib1510","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of Hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"10.1016\/j.jceh.2017.12.001_bib1515","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5301\/ijao.5000458","article-title":"Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population","volume":"38","author":"Fabrizi","year":"2015","journal-title":"Int J Artif Organs"},{"issue":"5","key":"10.1016\/j.jceh.2017.12.001_bib1520","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.semnephrol.2016.05.015","article-title":"Hepatitis viruses in kidney transplantation","volume":"36","author":"Gajurel","year":"2016","journal-title":"Semin Nephrol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688317305030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688317305030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:04:50Z","timestamp":1760853890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688317305030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0973688317305030"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2017.12.001","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017","name":"copyright","label":"Copyright"}]}}